Centessa Pharmaceuticals Announces CEO Transition as Company Advances Strategy to Extend Orexin Leadership into Multiple Neuroscience Indications

Mario Alberto Accardi PhD, President and founder of Centessa's Orexin Program, appointed Chief Executive Officer and member of the Board of Directors Mario Alberto Accardi PhD, President and founder of Centessa's Orexin Program, appointed Chief Executive Officer and member of the Board of Directors

GlobeNewsWire • Dec 11, 2025

What One Fund's Sale of Centessa Stock Signals About the Fast-Rising Biotech Company

San Francisco-based 5AM Venture Management sold 150,000 CNTA shares in the third quarter. Despite the sale, the stock's sharp rally last quarter led the fund's net position value in CNTA to increase by $5.6 million.

The Motley Fool • Nov 29, 2025

Centessa Stock Has Surged 77% Over the Past Year — But a Top Biotech Fund Is Still Buying

California-based TCG Crossover Management increased its stake in Centessa Pharmaceuticals by 245,664 shares in the third quarter for an estimated $38.1 million. The transaction value equaled about 0.2% of the fund's 13F reportable assets under management (AUM) at quarter-end.

The Motley Fool • Nov 17, 2025

Why Centessa Pharmaceuticals Stock Crushed the Market Today

It's gearing up to take in a flood of fresh capital. This is being effected in a secondary issue of its ADSes.

The Motley Fool • Nov 12, 2025

Centessa Pharmaceuticals Announces Proposed Public Offering of American Depositary Shares

BOSTON and LONDON, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today announced that it has commenced an underwritten public offering of American Depositary Shares (“ADSs”), each representing one ordinary share. All of the ADSs are being offered by Centessa.

GlobeNewsWire • Nov 11, 2025

Centessa Pharmaceuticals Announces Pricing of $250,000,000 Public Offering of American Depositary Shares

BOSTON and LONDON, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today announced the pricing of an underwritten public offering of 11,627,907 American Depositary Shares (“ADSs”), each representing one ordinary share, at a price to the public of $21.50 per ADS. The aggregate gross proceeds to Centessa from this offering are expected to be approximately $250 million, before deducting underwriting discounts and commissions and offering expenses payable by Centessa. All ADSs sold in the offering were offered by Centessa. The offering is expected to close on or about November 14, 2025, subject to customary closing conditions. Centessa has also granted the underwriters a 30-day option to purchase up to an additional 1,744,186 ADSs at the public offering price, less underwriting discounts and commissions.

GlobeNewsWire • Nov 12, 2025

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

BOSTON and LONDON, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the following investor conferences: Event: Guggenheim 2nd Annual Healthcare Innovation Conference Date: Wednesday, November 12, 2025 Fireside Chat: 10:30 AM ET Event: Jefferies Global Healthcare Conference in London Date: Tuesday, November 18, 2025 Fireside Chat: 2:00 PM GMT/ 9:00 AM ET Event: 37th Annual Piper Sandler Healthcare Conference Date: Tuesday, December 2, 2025 Fireside Chat: 3:00 PM ET Event: 8th Annual Evercore Healthcare Conference Date: Wednesday, December 3, 2025 Fireside Chat: 9:35 AM ET Event: Oppenheimer Movers in Rare Disease Summit Date: Thursday, December 11, 2025 Access to the live webcasts of these events, as well as archived recordings, will be available under the “Events and Publications” tab on the investor relations section of the Centessa Pharmaceuticals website at https://investors.centessa.com/. About Centessa Pharmaceuticals Centessa Pharmaceuticals, plc is a clinical-stage pharmaceutical company with a mission to discover, develop and ultimately deliver medicines that are transformational for patients.

GlobeNewsWire • Nov 7, 2025

Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2025 and Provides Update on Potential Best-in-Class Orexin Receptor 2 (OX2R) Agonist Program

BOSTON and LONDON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today reported financial results for the third quarter ended September 30, 2025 and provided an update on its OX2R agonist program, including Phase 2a data1 from the initial dosing cohorts within the ongoing CRYSTAL-1 study of ORX750 in NT1, NT2 and IH participants, and Phase 1 data2 from the ongoing study of ORX142 in healthy volunteers.

GlobeNewsWire • Nov 5, 2025

Centessa Pharmaceuticals to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

BOSTON and LONDON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference in New York, NY.

GlobeNewsWire • Sep 3, 2025

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2025

Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise, with key data readouts expected this year

GlobeNewsWire • Aug 12, 2025